B-type natriuretic peptide and C-terminal-pro-endothelin-1 for the prediction of severely impaired peak oxygen consumption
- PMID: 19226375
- DOI: 10.1111/j.1365-2796.2009.02071.x
B-type natriuretic peptide and C-terminal-pro-endothelin-1 for the prediction of severely impaired peak oxygen consumption
Abstract
Objective: To assess the utility of B-type natriuretic peptide (BNP) and C-terminal-pro-endothelin-1 (CT-proET-1) to predict a severely impaired peak oxygen consumption (peak VO(2), < 14 mL kg(-1) min(-1)) in patients referred for cardiopulmonary exercise testing.
Design: Cross-sectional study.
Setting: Tertiary care center.
Methods: Peak VO(2), BNP and CT-proET-1 were assessed in 141 consecutive patients referred for cardiopulmonary exercise testing.
Results: B-type natriuretic peptide [median (interquartile range) 48 (38-319) vs. 33 (15-86) pg mL(-1); P = 0.002] and CT-proET-1 [87 (76-95) vs. 60 (52-74) pmol L(-1); P < 0.001] were higher in patients with a peak VO(2) < 14 mL kg(-1) min(-1) (n = 30) than in those with a peak VO(2) > or = 14 mL kg(-1) min(-1) (n = 111). CT-pro-ET-1 had a higher area under the receiver-operator-characteristics curve (AUC) to predict a peak VO(2) < 14 mL kg(-1) min(-1) than BNP (0.79 vs. 0.68; P = 0.04). The optimal BNP cut-off of 37.2 pg mL(-1) had a sensitivity of 80% and a specificity of 56%. The optimal CT-proET-1 cut-off of 74.4 pmol L(-1) had a sensitivity of 80% and specificity of 76%. A five-item score composed of body mass index, diabetes, forced expiratory volume within the first second, alveolo-arterial oxygen pressure difference, and BNP had an AUC of 0.88 to predict a peak VO(2) < 14 mL kg(-1) min(-1). Adding CT-proET-1 to the score resulted in an AUC of 0.92.
Conclusions: C-terminal-pro-endothelin-1 is superior to BNP for the prediction of a peak VO(2) < 14 mL kg(-1) min(-1) in patients referred for CPET. A score incorporating body mass index, diabetes status, spirometry, blood gases, BNP and CT-proET-1 improves the prediction of a peak VO(2) < 14 mL kg(-1) min(-1) based on single biomarkers.
Similar articles
-
Natriuretic peptides for the prediction of severely impaired peak VO2 in patients with lung disease.Respir Med. 2009 Sep;103(9):1337-45. doi: 10.1016/j.rmed.2009.03.015. Epub 2009 Apr 16. Respir Med. 2009. PMID: 19375295
-
N-terminal prohormone brain natriuretic peptide as a marker for detecting low functional class patients and candidates for cardiac transplantation: linear correlation with exercise tolerance.J Heart Lung Transplant. 2007 May;26(5):516-21. doi: 10.1016/j.healun.2007.01.026. Epub 2007 Mar 21. J Heart Lung Transplant. 2007. PMID: 17449423
-
B-type natriuretic peptides for the evaluation of exercise intolerance.Am J Med. 2009 Mar;122(3):265-72. doi: 10.1016/j.amjmed.2008.08.030. Am J Med. 2009. PMID: 19272488
-
Individual patient meta-analysis of exercise training effects on systemic brain natriuretic peptide expression in heart failure.Eur J Prev Cardiol. 2012 Jun;19(3):428-35. doi: 10.1177/1741826711409171. Epub 2011 May 4. Eur J Prev Cardiol. 2012. PMID: 21543459 Review.
-
A meta-analysis of the utility of pre-operative brain natriuretic peptide in predicting early and intermediate-term mortality and major adverse cardiac events in vascular surgical patients.Anaesthesia. 2008 Nov;63(11):1226-33. doi: 10.1111/j.1365-2044.2008.05574.x. Epub 2008 Jul 31. Anaesthesia. 2008. PMID: 18673363 Review.
Cited by
-
Midregional pro-adrenomedullin and copeptin: exercise kinetics and association with the cardiopulmonary exercise response in comparison to B-type natriuretic peptide.Eur J Appl Physiol. 2014 Apr;114(4):815-24. doi: 10.1007/s00421-013-2815-4. Epub 2014 Jan 5. Eur J Appl Physiol. 2014. PMID: 24390725
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous